Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash from Financing Activities: 2023-2025

Historic Cash from Financing Activities for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $348,000.

  • Monte Rosa Therapeutics' Cash from Financing Activities rose 2220.00% to $348,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 98.92%. This contributed to the annual value of $98.9 million for FY2024, which is 259.71% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Cash from Financing Activities stood at $348,000 for Q3 2025, which was down 4.66% from $365,000 recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Cash from Financing Activities high stood at $98.0 million for Q2 2024, and its period low was $14,000 during Q1 2025.
  • Moreover, its 3-year median value for Cash from Financing Activities was $365,000 (2025), whereas its average is $11.6 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first spiked by 8,068.58% in 2024, then slumped by 99.63% in 2025.
  • Monte Rosa Therapeutics' Cash from Financing Activities (Quarterly) stood at $25.2 million in 2023, then crashed by 97.58% to $608,000 in 2024, then spiked by 2,220.00% to $348,000 in 2025.
  • Its last three reported values are $348,000 in Q3 2025, $365,000 for Q2 2025, and $14,000 during Q1 2025.